Menu Search
Equities

Scinai Immunotherapeutics Ltd

2F50:FRA

Scinai Immunotherapeutics Ltd

Actions
  • Price (EUR)0.414
  • Today's Change0.002 / 0.49%
  • Shares traded50.00
  • 1 Year change-73.80%
  • Beta--
Data delayed at least 15 minutes, as of May 13 2024 14:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

  • Revenue in USD (TTM)0.00
  • Net income in USD-9.29m
  • Incorporated2003
  • Employees33.00
  • Location
    Scinai Immunotherapeutics LtdJerusalem Biopark2Nd Floor, Hadassah Ein Kerem CampusJERUSALEM 00000IsraelISR
  • Phone+972 89302529
  • Fax+972 89302531
  • Websitehttps://www.scinai.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.